Allison Dorval was appointed as a director of Puma Biotechnology, effective July 15, 2021. Ms. Dorval has served as Chief Financial Officer of Voyager Therapeutics, Inc., a public clinical stage gene therapy company, since November 2018 and as Voyager’s principal financial officer and principal accounting officer since June 2018. Ms. Dorval joined Voyager as its Vice President of Finance in June 2017 and is a certified public accountant.
Prior to joining Voyager, Ms. Dorval served as Vice President and Controller of Juniper Pharmaceuticals, Inc., a biopharmaceutical company, from August 2016 to June 2017, and as a consultant at Danforth Advisors, a life sciences consultancy focusing on accounting and financial matters, from September 2015 to August 2016. In connection with her role at Danforth, Ms. Dorval served as interim Chief Financial Officer of medical device companies 480 Biomedical, Inc. and Arsenal Medical, Inc. from December 2015 to August 2016. Previously, Ms. Dorval served in several roles at Insulet Corporation, a medical device company, from August 2008 to July 2015, including as Chief Financial Officer from November 2014 to May 2015 and as Vice President and Controller from August 2008 to November 2014. Earlier in her career, Ms. Dorval served in various financial and accounting capacities at iBasis, Inc., a telecommunications company; Digitas Inc., an advertising company; and PricewaterhouseCoopers LLP.
Ms. Dorval received a B.S. in Business Administration from the University of Vermont and has completed a graduate-level certificate program in Taxation at Bentley University’s McCallum Graduate School of Business. Ms. Dorval was selected as a director because of her extensive background in finance and accounting and her experience in the life sciences industry.
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024